Evolution of vitreomacular traction following the use of the dexamethasone intravitreal implant (Ozurdex) in the treatment of macular edema secondary to central retinal vein occlusion
- PMID: 22537269
- DOI: 10.1089/jop.2011.0184
Evolution of vitreomacular traction following the use of the dexamethasone intravitreal implant (Ozurdex) in the treatment of macular edema secondary to central retinal vein occlusion
Abstract
Purpose: To report a case of worsening of vitreomacular traction (VMT) after the dexamethasone intravitreal implant (Ozurdex; Allergan, Inc., Irvine, CA) for the treatment of macular edema secondary to central retinal vein occlusion (CRVO).
Case: A 71-year-old man who presented with macular edema secondary to CRVO was treated by intravitreal injections of bevacizumab followed by Ozurdex.
Results: VMT developed during the course of treatment and became more evident when macular edema resolved after treatment with Ozurdex.
Conclusion: VMT may become apparent and worsen after resolution of macular edema treated with intravitreal Ozurdex.
Comment in
-
Vitreous traction after Ozurdex injection.J Ocul Pharmacol Ther. 2013 Feb;29(1):3-4. doi: 10.1089/jop.2012.0130. Epub 2012 Oct 25. J Ocul Pharmacol Ther. 2013. PMID: 23098563 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
